Antibe Therapeutics, Inc. (OTC:ATBPF) (TSX:ATE.TO) is developing otenaproxesul as a solution to the dose-related gastrointestinal (GI) side effects associated with non-steroidal anti-inflammatory ...
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Operative today announced the appointment of Mike Napodano as Chief Executive Officer, marking the next step in the company’s evolution as it accelerates ...
SAN DIEGO--(BUSINESS WIRE)--Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on developing novel best-in-class treatment solutions to address some of the ...
Trial in progress: A multicenter phase II study of pembrolizumab in patients with advanced small bowel adenocarcinomas. Background: Standard therapy for resectable and borderline resectable pancreatic ...
PARSIPPANY, N.J., Dec. 1 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., announced today that its second Phase III placebo controlled study of EXPAREL(TM) (DepoBupivacaine) met its primary endpoint. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback